A clinical trial of silver-coated and tapered cuff plus supraglottic suctioning endotracheal tubes in preventing ventilator-associated pneumonia
A clinical trial of silver-coated and tapered cuff plus supraglottic suctioning endotracheal tubes in preventing ventilator-associated pneumonia
نویسندگان: عطا محمودپور , سروین سنایی اسکویی , کامران شادور , هادی همیشه کار , سما رهنمایان , حمیدرضا نوری
کلمات کلیدی: Endotracheal tubes; Mortality; Ventilator-associated Pneumonia; Silver-coated
Bactiguard; Subglottic suctioning; Taperguard Evac
نشریه: 19875 , 2020 , 56 , 2020
| نویسنده ثبت کننده مقاله |
عطا محمودپور |
| مرحله جاری مقاله |
تایید نهایی |
| دانشکده/مرکز مربوطه |
دانشکده پزشکی |
| کد مقاله |
71834 |
| عنوان فارسی مقاله |
A clinical trial of silver-coated and tapered cuff plus supraglottic suctioning endotracheal tubes in preventing ventilator-associated pneumonia |
| عنوان لاتین مقاله |
A clinical trial of silver-coated and tapered cuff plus supraglottic suctioning endotracheal tubes in preventing ventilator-associated pneumonia |
| ناشر |
9 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ |
بلی |
| عنوان نشریه (خارج از لیست فوق) |
|
| نوع مقاله |
Original Article |
| نحوه ایندکس شدن مقاله |
ایندکس شده سطح یک – ISI - Web of Science |
| آدرس لینک مقاله/ همایش در شبکه اینترنت |
|
| 1. Abstract:
Purpose: Novel designs of the endotracheal tube (ETT) are emerged to reduce the risk of
ventilator-associated pneumonia (VAP). We evaluated the effect of two different types, namely
silver-coated (Bactiguard) and subglottic suctioning (Taperguard) ETTs, on the incidence of
VAP in critically- ill patients.
Methods: A total of 90 patients, mechanically ventilated for more than 72 hours, were randomly
assigned to Bactiguard and Taperguard groups. They otherwise received routine care, including
VAP prevention measures during their intensive care unit (ICU) stay. Subglottic suctioning was
performed in Taperguard group. Statistical analyses were performed using SPSS 25 for iMacs.
Results: Both groups had similar demographics and did not differ in the prevalence of
comorbidities and the severity of underlying illness. There was no difference in the frequency of
reintubation (P=0.565), the duration of ventilation, ICU and total hospital length of stay. VAP
developed in 31% of the Bactiguard group and 20% of the Taperguard group (P=0.227). Nearly twice the number of patients died in the Bactiguard group compared to the Taperguard group.
This difference was not significant either (P=0.352).
Conclusions: The use of Bactiguard or Taperguard ETTs was not associated with any difference
in the incidence of VAP or ICU mortality. |
| نام فایل |
تاریخ درج فایل |
اندازه فایل |
دانلود |
| 1.pdf | 1399/05/14 | 593134 | دانلود |
| wuttgpnpdynafbak.pdf | 1399/02/07 | 176875 | دانلود |